USA - NYSE:CLB - US21867A1051 - Common Stock
The current stock price of CLB is 15.96 USD. In the past month the price increased by 33.22%. In the past year, price decreased by -15.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SLB | SLB LTD | 11.83 | 54.26B | ||
| BKR | BAKER HUGHES CO | 19.28 | 47.89B | ||
| HAL | HALLIBURTON CO | 11.09 | 22.99B | ||
| TS | TENARIS SA-ADR | 8.48 | 20.75B | ||
| FTI | TECHNIPFMC PLC | 18.17 | 17.18B | ||
| NOV | NOV INC | 15.12 | 5.61B | ||
| WFRD | WEATHERFORD INTERNATIONAL PL | 15.91 | 5.21B | ||
| AROC | ARCHROCK INC | 18.68 | 4.47B | ||
| SEI | SOLARIS ENERGY INFRASTRUCTUR | 71.77 | 3.59B | ||
| WHD | CACTUS INC - A | 15.58 | 3.45B | ||
| KGS | KODIAK GAS SERVICES INC | 30.59 | 3.23B | ||
| LBRT | LIBERTY ENERGY INC | 23.12 | 3.03B |
Core Laboratories Inc. provides proprietary and patented reservoir description and production enhancement services. The company is headquartered in Houston, Texas and currently employs 3,500 full-time employees. The company went IPO on 2018-10-22. The firm helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. The company makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. The company assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
CORE LABORATORIES INC
6316 Windfern Road
Houston TEXAS 1077 XX US
CEO: Lawrence Bruno
Employees: 3300
Phone: 17133282673
Core Laboratories Inc. provides proprietary and patented reservoir description and production enhancement services. The company is headquartered in Houston, Texas and currently employs 3,500 full-time employees. The company went IPO on 2018-10-22. The firm helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. The company makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. The company assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
The current stock price of CLB is 15.96 USD. The price decreased by -0.93% in the last trading session.
CORE LABORATORIES INC (CLB) has a dividend yield of 0.24%. The yearly dividend amount is currently 0.04.
CLB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
CLB stock is listed on the New York Stock Exchange, Inc. exchange.
CORE LABORATORIES INC (CLB) operates in the Energy sector and the Energy Equipment & Services industry.
The Revenue of CORE LABORATORIES INC (CLB) is expected to decline by -2.71% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ChartMill assigns a technical rating of 7 / 10 to CLB. When comparing the yearly performance of all stocks, CLB is one of the better performing stocks in the market, outperforming 77.64% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to CLB. CLB has an excellent financial health rating, but there are some minor concerns on its profitability.
Over the last trailing twelve months CLB reported a non-GAAP Earnings per Share(EPS) of 0.77. The EPS decreased by -9.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.21% | ||
| ROA | 5.43% | ||
| ROE | 11.84% | ||
| Debt/Equity | 0.42 |
11 analysts have analysed CLB and the average price target is 15.64 USD. This implies a price decrease of -2.01% is expected in the next year compared to the current price of 15.96.
For the next year, analysts expect an EPS growth of -13.84% and a revenue growth -2.71% for CLB